Moteur de recherche d’entreprises européennes
Financement de l’UE (8 728 185 €) : Accélérer le développement et améliorer l’accès à la thérapie par lymphocytes T CAR et TCR Hor26/11/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Accélérer le développement et améliorer l’accès à la thérapie par lymphocytes T CAR et TCR
Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative novel treatment that has the potential to cure cancer. Multiple new versions of this therapy are being developed for distinct types of cancer but their introduction into clinical practice is hampered by a lack of standardized and validated models to predict safety and efficacy, customized manufacturing and monitoring to scale up production and clinical use to industry standard, and strategies for optimal patient conditioning. The T2EVOLVE consortium unites scientists and physicians, regulators and policy makers, SMEs, and patient stakeholders to tackle these challenges in an orchestrated multi-disciplinary multi-stakeholder approach. A core feature of this approach will be the embedding of patient stakeholders as contributing members of the team across all levels of the R&D process. The overall aim is the development of an innovation ecosystem that will accelerate the process of developing engineered T cell therapy in the EU. The project will deliver novel tools for education and for improving the communication between healthcare providers and patients, optimized laboratory models that can help determine how safe and effective new therapies with engineered T cells are, standardized methods in which these therapies are produced and monitored during treatment. The consortium members are innovators and pioneers in this field that are dedicated to bringing the EU to the forefront of the global engineered T cell therapy movement. This effort will ensure that EU citizens will continue to have access to the most innovative and best-available medical care, provide guidance on how to implement this novel treatment into the EU health care system in a sustainable way, and secure a leading role for Europe in this emerging field in medicine and science, the economy and society.
| 718 625 € | |
| Astellas Pharma Europe B.V. | 0,00 € |
| BAYER AG | 0,00 € |
| BUNDESINSTITUT für IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL | 479 000 € |
| Biosci Consulting BVBA | 476 000 € |
| CELGENE MANAGEMENT Sàrl | 0,00 € |
| Erasmus Universiteit Rotterdam | 78 125 € |
| European Cancer Patient Coalition | 37 621 € |
| 0,00 € | |
| 0,00 € | |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 539 750 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 510 689 € |
| Hospital Clinic de Barcelona | 0,00 € |
| Information Technology FOR Translational Medicine (Ittm) SA | 312 500 € |
| 454 000 € | |
| Institut National du Cancer GIP | 551 260 € |
| Institut de Recerca de L'Hospital de La Santa Creu i Sant Pau Fundacion | 271 310 € |
| Institut de Recherches Internationales Servier Iris | 0,00 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| MILTENYI BIOTEC B.V. & Co. KG | 277 500 € |
| Medizinische Universitaet Wien | 571 911 € |
| Ospedale Pediatrico Bambino Gesu | 560 600 € |
| PATVOCATES GmbH | 87 600 € |
| Stichting Amsterdam UMC | 0,00 € |
| T-CURX GmbH | 253 750 € |
| TAKEDA PHARMACEUTICALS INTERNATIONAL AG | 0,00 € |
| TECHNISCHE UNIVERSITAET MUENCHEN | 562 750 € |
| UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT | 612 774 € |
| Universidad de Navarra | 271 370 € |
| Universita Vita-Salute SAN Raffaele | 629 550 € |
| University College London | 471 500 € |
https://cordis.europa.eu/project/id/945393
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Academisch Medisch Centrum BIJ DE Universiteit Van Amsterdam - Financement de l’UE (8 728 185 €) : Accélérer le développement et améliorer l’accès à la thérapie par lymphocytes T CAR et TCR"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
